UK: The MHRA provides regulatory flexibilities resulting from COVID-19

By Published On: June 8th, 20201 min read

UK: The MHRA provides regulatory flexibilities resulting from COVID-19

By Published On: June 8th, 20201 min read

The MHRA updated its Guidance for industry on flexible approaches to regulation they are taking during the COVID-19 outbreak.

dded information on audits of Notified Bodies and manufacturers in the ‘Medical Devices’ section. Where feasible, audits of Notified Bodies and manufacturers have been delayed. Remote audits and reviews are being considered as alternatives.

Contents

  1. Making use of regulatory flexibilities
  2. Clinical trials
  3. Marketing authorisations
  4. Pharmacovigilance
  5. Inspections and good practice
  6. Blood components for transfusion
  7. Medical devices

For more details, please see the original communication from the MHRA.

Meditrial has developed rapid workflows to conduct risk assessment, implement rescue plans and execute solutions for ongoing clinical trials:

Contact Meditrial for immediate assistance in Europe or the US.

Table of Contents

Latest Articles

This article provides general information and does not constitute regulatory, legal, clinical, or compliance advice. Requirements and appropriate processes may vary by study, product, jurisdiction, and organization. Medigen Suite functionality should be used in accordance with applicable regulations, study documentation, and internal procedures.

Go to Top